PureTech affiliate Karuna advances schizophrenia candidate

16th October 2018 Uncategorised 0

Karuna Pharmaceuticals, an affiliate of UK-listed biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.

More: PureTech affiliate Karuna advances schizophrenia candidate
Source: News